CanSino Biologics Inc is a CN-based company operating in Biotechnology industry. The company is headquartered in Tianjin, Tianjin and currently employs 1,105 full-time employees. The company went IPO on 2019-03-28. CanSino Biologics Inc is a China-based company primarily engaged in the research and development, production, and commercialization of human vaccine products. The Company’s products and product pipeline under research include multiple vaccine varieties such as meningitis, pneumonia, diphtheria, tetanus, and pertussis (DPT), coronavirus disease 2019 (COVID-19), Ebola virus disease, poliomyelitis, herpes zoster, tuberculosis and others. The firm is also engaged in the research and development of pharmaceutical production processes. The firm conducts its business in the domestic and overseas markets.
Follow-Up Questions
CanSino Biologics Inc 的 CEO 是誰？
Mr. Xuefeng Yu 是 CanSino Biologics Inc 的 Executive Chairman of the Board，自 2009 加入公司。
CASBF 股票的價格表現如何？
CASBF 的當前價格為 $6.6，在上個交易日 decreased 了 0%。
CanSino Biologics Inc 的主要業務主題或行業是什麼？
CanSino Biologics Inc 屬於 Biotechnology 行業，該板塊是 Health Care
